CO6910198A2 - Compuestos y métodos para mejorar las respuestas inmunitarias innatas - Google Patents
Compuestos y métodos para mejorar las respuestas inmunitarias innatasInfo
- Publication number
- CO6910198A2 CO6910198A2 CO14058151A CO14058151A CO6910198A2 CO 6910198 A2 CO6910198 A2 CO 6910198A2 CO 14058151 A CO14058151 A CO 14058151A CO 14058151 A CO14058151 A CO 14058151A CO 6910198 A2 CO6910198 A2 CO 6910198A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- methods
- immune responses
- innate immune
- improve innate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000015788 innate immune response Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549784P | 2011-10-21 | 2011-10-21 | |
| US201261692431P | 2012-08-23 | 2012-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6910198A2 true CO6910198A2 (es) | 2014-03-31 |
Family
ID=48141628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14058151A CO6910198A2 (es) | 2011-10-21 | 2014-03-18 | Compuestos y métodos para mejorar las respuestas inmunitarias innatas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140249143A1 (enExample) |
| EP (1) | EP2768506A4 (enExample) |
| JP (1) | JP2014532626A (enExample) |
| KR (1) | KR20140094559A (enExample) |
| CN (1) | CN103957910A (enExample) |
| AR (1) | AR088793A1 (enExample) |
| AU (1) | AU2012325971B2 (enExample) |
| BR (1) | BR112014008727A2 (enExample) |
| CA (1) | CA2851801A1 (enExample) |
| CL (1) | CL2014001016A1 (enExample) |
| CO (1) | CO6910198A2 (enExample) |
| CR (1) | CR20140175A (enExample) |
| DO (1) | DOP2014000081A (enExample) |
| EA (1) | EA201490610A1 (enExample) |
| IL (1) | IL231894A0 (enExample) |
| MX (1) | MX2014004814A (enExample) |
| PE (1) | PE20141359A1 (enExample) |
| PH (1) | PH12014500865A1 (enExample) |
| SG (2) | SG11201400988SA (enExample) |
| TW (2) | TW201333003A (enExample) |
| UY (1) | UY34406A (enExample) |
| WO (1) | WO2013059559A2 (enExample) |
| ZA (1) | ZA201402392B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333168B (zh) * | 2013-07-23 | 2015-08-05 | 清华大学 | 一种酰胺类化合物及其制备方法与应用 |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| CA2963090A1 (en) | 2014-09-29 | 2016-04-07 | The Trustees Of The University Of Pennsylvania | Antivirals against molluscum contagiosum virus |
| CN104529893B (zh) * | 2014-12-30 | 2016-08-24 | 中国科学技术大学 | 一类可以作为高尔基体细胞器探针的喹啉染料 |
| CN105175277B (zh) * | 2015-05-18 | 2018-04-03 | 中山大学肿瘤防治中心 | 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用 |
| WO2018043747A1 (ja) * | 2016-09-05 | 2018-03-08 | 国立大学法人京都大学 | 抗ｂ型肝炎ウイルス剤 |
| JP2020512975A (ja) | 2017-03-28 | 2020-04-30 | ピメラ，インク． | Ｐｏｌ１阻害剤の新規な結晶形態 |
| US12134616B2 (en) | 2018-10-23 | 2024-11-05 | Basf Se | Tricyclic pesticidal compounds |
| CN114681472B (zh) * | 2019-03-13 | 2023-06-30 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
| EP4136086A1 (en) | 2020-04-14 | 2023-02-22 | Basf Se | Tricyclic pesticidal compounds |
| JP2023539896A (ja) * | 2020-09-03 | 2023-09-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｓａｒｓ－ｃｏｖ－２感染を治療するためのｉｆｎａｒ２アゴニストとしてのイミダゾナフチリジンおよびイミダゾピリドピリミジン |
| WO2022175425A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Intellectual Property Development Limited | Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection |
| US12030883B2 (en) | 2021-09-21 | 2024-07-09 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of KRAS |
| US12030884B2 (en) | 2021-10-01 | 2024-07-09 | Incyte Corporation | Pyrazoloquinoline KRAS inhibitors |
| KR20240101561A (ko) | 2021-10-14 | 2024-07-02 | 인사이트 코포레이션 | Kras의 저해제로서의 퀴놀린 화합물 |
| WO2023244672A1 (en) | 2022-06-14 | 2023-12-21 | Assembly Biosciences, Inc. | 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections |
| WO2024215912A1 (en) * | 2023-04-14 | 2024-10-17 | Humanwell Pharmacuetical Us | Monoacylglycerol lipase (magl) inhibitors for the treatment of pain and related medical disorders |
| JPWO2025089372A1 (enExample) * | 2023-10-26 | 2025-05-01 | ||
| WO2025128898A1 (en) | 2023-12-13 | 2025-06-19 | Assembly Biosciences, Inc. | Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections |
| WO2026084958A1 (en) | 2024-10-14 | 2026-04-23 | Assembly Biosciences, Inc. | Tricyclic heteroaryl compounds useful for enhancing innate immune responses |
| WO2026084957A1 (en) | 2024-10-14 | 2026-04-23 | Assembly Biosciences, Inc. | Tricyclic heteroaryl compounds useful for enhancing innate immune responses |
| WO2026084955A1 (en) | 2024-10-14 | 2026-04-23 | Assembly Biosciences, Inc. | Tricyclic heteroaryl compounds useful for enhancing innate immune responses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE441449B (sv) * | 1979-02-09 | 1985-10-07 | Roussel Uclaf | Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat |
| US4492697A (en) * | 1983-08-16 | 1985-01-08 | Ayerst, Mckenna & Harrison, Inc. | 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives |
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| RU2310657C2 (ru) * | 2002-04-03 | 2007-11-20 | Ф.Хоффманн-Ля Рош Аг | Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их |
| US8592368B2 (en) * | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| DE102005019181A1 (de) * | 2005-04-25 | 2006-10-26 | Novartis Ag | Peptid-Deformylase (PDF) Inhibitoren 1 |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JP5481671B2 (ja) * | 2009-03-31 | 2014-04-23 | ダイキン工業株式会社 | 高分子アクチュエータ素子用電極膜及びそれを有する高分子アクチュエータ素子 |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB201002409D0 (en) * | 2010-02-12 | 2010-03-31 | Univ Nottingham | Methods |
-
2012
- 2012-10-19 SG SG11201400988SA patent/SG11201400988SA/en unknown
- 2012-10-19 PE PE2014000559A patent/PE20141359A1/es not_active Application Discontinuation
- 2012-10-19 EA EA201490610A patent/EA201490610A1/ru unknown
- 2012-10-19 EP EP12840986.9A patent/EP2768506A4/en not_active Withdrawn
- 2012-10-19 AU AU2012325971A patent/AU2012325971B2/en not_active Ceased
- 2012-10-19 CA CA2851801A patent/CA2851801A1/en not_active Abandoned
- 2012-10-19 PH PH1/2014/500865A patent/PH12014500865A1/en unknown
- 2012-10-19 MX MX2014004814A patent/MX2014004814A/es unknown
- 2012-10-19 KR KR1020147013668A patent/KR20140094559A/ko not_active Withdrawn
- 2012-10-19 BR BR112014008727A patent/BR112014008727A2/pt not_active IP Right Cessation
- 2012-10-19 CN CN201280051347.8A patent/CN103957910A/zh active Pending
- 2012-10-19 JP JP2014537274A patent/JP2014532626A/ja active Pending
- 2012-10-19 WO PCT/US2012/060971 patent/WO2013059559A2/en not_active Ceased
- 2012-10-19 SG SG10201505664WA patent/SG10201505664WA/en unknown
- 2012-10-19 US US14/353,067 patent/US20140249143A1/en not_active Abandoned
- 2012-10-22 TW TW101138997A patent/TW201333003A/zh unknown
- 2012-10-22 TW TW104126180A patent/TW201542567A/zh unknown
- 2012-10-22 UY UY0001034406A patent/UY34406A/es not_active Application Discontinuation
- 2012-10-22 AR ARP120103945A patent/AR088793A1/es unknown
-
2014
- 2014-03-18 CO CO14058151A patent/CO6910198A2/es unknown
- 2014-03-31 ZA ZA2014/02392A patent/ZA201402392B/en unknown
- 2014-04-03 IL IL231894A patent/IL231894A0/en unknown
- 2014-04-21 CR CR20140175A patent/CR20140175A/es unknown
- 2014-04-21 CL CL2014001016A patent/CL2014001016A1/es unknown
- 2014-04-21 DO DO2014000081A patent/DOP2014000081A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY34406A (es) | 2013-05-31 |
| TW201333003A (zh) | 2013-08-16 |
| PH12014500865A1 (en) | 2014-05-26 |
| IL231894A0 (en) | 2014-05-28 |
| JP2014532626A (ja) | 2014-12-08 |
| AR088793A1 (es) | 2014-07-10 |
| TW201542567A (zh) | 2015-11-16 |
| KR20140094559A (ko) | 2014-07-30 |
| BR112014008727A2 (pt) | 2017-04-25 |
| EA201490610A1 (ru) | 2014-09-30 |
| WO2013059559A2 (en) | 2013-04-25 |
| CA2851801A1 (en) | 2013-04-25 |
| CL2014001016A1 (es) | 2015-01-16 |
| DOP2014000081A (es) | 2014-07-15 |
| ZA201402392B (en) | 2017-09-27 |
| SG10201505664WA (en) | 2015-09-29 |
| WO2013059559A3 (en) | 2013-11-14 |
| EP2768506A4 (en) | 2015-08-19 |
| AU2012325971A1 (en) | 2014-04-17 |
| US20140249143A1 (en) | 2014-09-04 |
| MX2014004814A (es) | 2014-05-27 |
| CR20140175A (es) | 2014-06-03 |
| AU2012325971B2 (en) | 2016-03-31 |
| SG11201400988SA (en) | 2014-07-30 |
| EP2768506A2 (en) | 2014-08-27 |
| PE20141359A1 (es) | 2014-10-13 |
| CN103957910A (zh) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291394A (en) | Dosing combinations for reducing undesired humoral immune responses | |
| IL283728A (en) | Tolerogenic synthetic nanocarriers to reduce antibody responses | |
| CO7020865A2 (es) | Microorganismos y métodos para producir alquenos | |
| BR112014006324A2 (pt) | método para tratar hcv | |
| BR112013023241A8 (pt) | melhorias para entidades biológicas imobilizadas | |
| PL3863288T3 (pl) | Sposoby intra-predykcji i środek nośnikowy | |
| PL2755389T3 (pl) | Sposób predykcji inter i urządzenie do niego | |
| BR112013033720A2 (pt) | método para tratar eczema | |
| HRP20161064T1 (hr) | Piridin-2-amidi korisni kao cb2-agonisti | |
| IL231894A0 (en) | Compounds and methods for enhancing innate immune responses | |
| BR112014013034A2 (pt) | método para produzir um anticorpo | |
| PL2928905T3 (pl) | Sposób oczyszczania białek terapeutycznych | |
| BR112014008691A2 (pt) | anticorpos para cd1d | |
| CO6870003A2 (es) | Vacunas bovinas y métodos | |
| BR112014000460A8 (pt) | método para produzir alimento seco | |
| CO6842021A2 (es) | Análogos de ácido epoxieicosatrienoico y métodos para elaborarlosy utilizarlos | |
| BR112013022254A2 (pt) | método e disposição para gerar oxigênio | |
| BR112013023465A2 (pt) | método para produzir l-cisteína | |
| IT1403906B1 (it) | Apparato e metodo per realizzare sbozzati | |
| CO7010822A2 (es) | Método para retardar la recticulación en operación de tratamiento de pozo | |
| BR112013033851A2 (pt) | método para formar sevoflurano | |
| BR112012027834A2 (pt) | método para produzir macarrão instântaneo e macarrão instântaneo | |
| BR112014003151A2 (pt) | métodos para produzir biodiesel | |
| IL231798A0 (en) | Method and composition | |
| BR112013030090A2 (pt) | métodos para tratar biomassa |